Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C49H54F2N8O6.C3H6O |
Molecular Weight | 947.079 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 6 / 6 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)=O.COC(=O)N[C@@H](C(C)C)C(=O)N1CC2(CC2)C[C@H]1C3=NC=C(N3)C4=CC5=C(C=C4)C6=C(C=C(C=C6)C7=CC=C8N=C(NC8=C7)[C@@H]9[C@H]%10CC[C@H](C%10)N9C(=O)[C@@H](NC(=O)OC)C(C)C)C5(F)F
InChI
InChIKey=FJPWYOHJVGOKNZ-NDANSHMASA-N
InChI=1S/C49H54F2N8O6.C3H6O/c1-24(2)39(56-46(62)64-5)44(60)58-23-48(15-16-48)21-38(58)42-52-22-37(55-42)28-9-13-32-31-12-8-26(18-33(31)49(50,51)34(32)19-28)27-10-14-35-36(20-27)54-43(53-35)41-29-7-11-30(17-29)59(41)45(61)40(25(3)4)57-47(63)65-6;1-3(2)4/h8-10,12-14,18-20,22,24-25,29-30,38-41H,7,11,15-17,21,23H2,1-6H3,(H,52,55)(H,53,54)(H,56,62)(H,57,63);1-2H3/t29-,30+,38-,39-,40-,41-;/m0./s1
Molecular Formula | C3H6O |
Molecular Weight | 58.0791 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C49H54F2N8O6 |
Molecular Weight | 888.9999 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 6 / 6 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionCurator's Comment: description was created based on several sources, including http://www.ncbi.nlm.nih.gov/pubmed/?term=23384816; http://www.ncbi.nlm.nih.gov/pubmed/?term=22314425
Curator's Comment: description was created based on several sources, including http://www.ncbi.nlm.nih.gov/pubmed/?term=23384816; http://www.ncbi.nlm.nih.gov/pubmed/?term=22314425
Ledipasvir is an inhibitor of the Hepatitis C Virus (HCV) NS5A protein required for viral RNA replication and assembly of HCV virions. Approved in October 2014 by the FDA, ledipasvir and sofosbuvir (tradename Harvoni) are direct-acting antiviral agents indicated for the treatment of HCV genotype 1 with or without cirrhosis.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL3307224 Sources: http://www.ncbi.nlm.nih.gov/pubmed/?term=23384816 |
141.0 nM [EC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | HARVONI Approved UseIndicated for the treatment of patients with chronic hepatitis C virus (HCV) genotype 1, 4, 5, or 6 infection Launch Date2014 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
323 ng/mL |
90 mg 1 times / day steady-state, oral dose: 90 mg route of administration: Oral experiment type: STEADY-STATE co-administered: [NO STEREO] PSI-7851|[NO STEREO] SOFOSBUVIR |
[NO STEREO] LEDIPASVIR plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
531 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31220349/ |
45 mg 1 times / day multiple, oral dose: 45 mg route of administration: Oral experiment type: MULTIPLE co-administered: [NO STEREO] PSI-7851|[NO STEREO] SOFOSBUVIR |
[NO STEREO] LEDIPASVIR plasma | Homo sapiens population: UNHEALTHY age: CHILD sex: FEMALE / MALE food status: FED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
7290 ng × h/mL |
90 mg 1 times / day steady-state, oral dose: 90 mg route of administration: Oral experiment type: STEADY-STATE co-administered: [NO STEREO] PSI-7851|[NO STEREO] SOFOSBUVIR |
[NO STEREO] LEDIPASVIR plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
9320 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31220349/ |
45 mg 1 times / day multiple, oral dose: 45 mg route of administration: Oral experiment type: MULTIPLE co-administered: [NO STEREO] PSI-7851|[NO STEREO] SOFOSBUVIR |
[NO STEREO] LEDIPASVIR plasma | Homo sapiens population: UNHEALTHY age: CHILD sex: FEMALE / MALE food status: FED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
47 h |
90 mg 1 times / day steady-state, oral dose: 90 mg route of administration: Oral experiment type: STEADY-STATE co-administered: [NO STEREO] PSI-7851|[NO STEREO] SOFOSBUVIR |
[NO STEREO] LEDIPASVIR plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
0.2% |
90 mg 1 times / day steady-state, oral dose: 90 mg route of administration: Oral experiment type: STEADY-STATE co-administered: [NO STEREO] PSI-7851|[NO STEREO] SOFOSBUVIR |
[NO STEREO] LEDIPASVIR plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
90 mg 1 times / day multiple, oral Highest studied dose Dose: 90 mg, 1 times / day Route: oral Route: multiple Dose: 90 mg, 1 times / day Sources: |
unhealthy, 49 years n = 10 Health Status: unhealthy Condition: genotype 1 hepatitis C Age Group: 49 years Sex: M+F Population Size: 10 Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
Changing the face of hepatitis C management - the design and development of sofosbuvir. | 2015 |
|
Ledipasvir and sofosbuvir: Interferon free therapy for hepatitis C virus genotype 1 infection. | 2015 Feb 12 |
|
Treatment with ledipasvir and sofosbuvir improves patient-reported outcomes: Results from the ION-1, -2, and -3 clinical trials. | 2015 Jun |
|
Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection. | 2015 Mar 24-31 |
|
Interferon-free therapy for hepatitis C: The hurdles amid a golden era. | 2015 Sep |
Patents
Sample Use Guides
One tablet (90 mg of ledipasvir and 400 mg of sofosbuvir) taken orally once daily with or without food. Recommended treatment duration: treatment-naive with or without cirrhosis: 12 week. Treatment-experienced without cirrhosis: 12 weeks. Treatment-experienced with cirrhosis: 24 weeks. A dose recommendation cannot be made for patients with severe renal impairment or end stage renal disease.
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 18:30:39 GMT 2023
by
admin
on
Sat Dec 16 18:30:39 GMT 2023
|
Record UNII |
3J78ET35HX
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
300000001120
Created by
admin on Sat Dec 16 18:30:39 GMT 2023 , Edited by admin on Sat Dec 16 18:30:39 GMT 2023
|
PRIMARY | |||
|
3J78ET35HX
Created by
admin on Sat Dec 16 18:30:39 GMT 2023 , Edited by admin on Sat Dec 16 18:30:39 GMT 2023
|
PRIMARY | |||
|
1441674-54-9
Created by
admin on Sat Dec 16 18:30:39 GMT 2023 , Edited by admin on Sat Dec 16 18:30:39 GMT 2023
|
PRIMARY | |||
|
78357793
Created by
admin on Sat Dec 16 18:30:39 GMT 2023 , Edited by admin on Sat Dec 16 18:30:39 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |